Avalo Therapeutics is a clinical-stage biotechnology company developing IL-1β-targeted treatments for immune-mediated inflammatory diseases, with a lead product candidate, abdakibart, a humanized monoclonal antibody in Phase 2 trials for hidradenitis suppurativa, a chronic inflammatory skin disease with significant unmet clinical need despite existing biologic options. The company licenses its lead compound exclusively from Eli Lilly and generates revenue through milestone payments and royalties contingent on regulatory approval and net sales. Avalo competes in a crowded market against major pharmaceutical companies and faces regulatory uncertainty, manufacturing dependencies on third-party contract organizations, and the need to build commercial infrastructure for eventual product launch.